Cardiac Biomarker ST2 Identifies Chronic Heart Failure Patients To Benefit from High-Dose Beta Blocker Therapy

SAN DIEGO--(BUSINESS WIRE)--Mar 12, 2013 - Critical Diagnostics, makers of the Presage® ST2 Assay, announced today that during a presentation this week at the American College of Cardiology Scientific Sessions in San Francisco, the results of a study conducted through the Massachusetts General Hospital, Circulating Concentrations of Soluble ST2 Identify Benefit of High Dose Beta Blocker in Chronic Heart Failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study, highlighted the cardiac biomarker ST2's ability to identify those patients most likely to benefit from high-dose beta blockers and reduce risk from cardiovascular complications.

The 151 study participants were followed for 10 months and ST2 levels were measured using the Presage® ST2 Assay. Individuals with high ST2 concentrations and low beta blocker dose were more than four times as likely to result in a cardiovascular event and the least likely to survive, than those with low ST2 concentrations and high beta blocker dosage. Furthermore, ST2 levels “predicted time-to-first cardiovascular event above and beyond NT-proBNP and baseline clinical characteristics.”

“The findings of this study provide the foundation of ST2 in guiding personalized therapy for chronic heart failure patients,” notes Dr. James Snider, President of Critical Diagnostics. “ST2 is unlike any biomarker in heart failure because of its enduring prognostic strength, but now, as evidenced by the encouraging results from this study, ST2 holds the final link in potentially improving outcomes for heart failure patients through its unique ability to identify those who can benefit most from high-dose beta blocker treatment.”

“This is where the rubber meets the road in heart failure management,” exclaimed David Geliebter, Chairman and CEO of Critical Diagnostics. “While one aspect in heart failure management is to identify those patients at highest risk, it is just as important, however, if not crucial, to have the ability to measure progress in the selected treatment. ST2 continues to build evidence as the most versatile, prognostic cardiac biomarker in heart failure.”

About ST2

Soluble ST2 has now been published in more than 50 peer-reviewed articles studying more than 31,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent of, and provides added information to, that of cardiac biomarkers commonly used today, including the natriuretic peptides BNP and NT-proBNP.

About Critical Diagnostics

Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage ST2 Assay has been CE Marked and cleared by the US FDA for use in risk stratification with chronic heart failure patients. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.

Contact: Critical Diagnostics
Dennis Dalangin, 877-700-1250
VP Marketing
ddalangin@criticaldiagnostics.com

 

Posted: March 2013

View comments

Hide
(web2)